Oxford Outcomes Oxford Outcomes Oxford Outcomes Oxford Outcomes

Utility measurement

Oxford Outcomes has long-standing expertise and experience of measuring utilities, and their successful integration into economic evaluation.   This core strength derives from the strength and depth of our well-established PRO and Health Economics teams.  With these scientific foundations, we are able to design utility studies that optimise scientific validity, sensitivity to health state differences, and the methodological rigours required for economic evaluation.

Oxford Outcomes has expertise in a range of utility methods to meet the requirements of national and regional reimbursement agencies such as NICE, SMC, CDR, and PBAC, including: 

  • Prospective observational studies utilising validated measures such as EQ-5D.
  • Societal, patient or proxy valuations, using direct elicitation methods (standard gamble, time trade-off and utility mapping).
  • Development of statistical algorithms for estimating utilities from disease specific and generic health status measures.
  • Deriving a preference-based measure from a condition-specific or generic health instrument (utility mapping).
  • Development and valuation of vignettes in order to capture health state utilities and the disutilities associated with adverse events.
  • Specialist analysis methods for observational and trial data.

Utilities are gaining importance as a measure of health status. Several key healthcare markets now require manufacturers to demonstrate cost effectiveness as part of their reimbursement process.  This analysis is derived from health state evaluation in the form of an incremental cost per Quality Adjusted Life Year (QALY). QALYs are a product of survival and quality of life, where quality of life is represented as a utility value. 

Oxford Outcomes can add value to reimbursement submissions by assessing at an early stage, the validity and sensitivity of published utility data and, if necessary, design studies that will capture all of the benefits of treatment and maximise the chance of demonstrating cost effectiveness.  Reimbursement agencies play close attention to the quality of the utility data used in reimbursement submissions, and the number of rejections is testimony to this trend.